Key facts
- Spear Bio’s last known valuation is $134.0M.
- It has raised $69.8M across 4 recorded rounds; the latest was Early Stage VC ($45.0M) in Jul 2024.
- Notable investors include Hongshan Capital Group, CDH Investments, Yonghua Capital, Foresite Capital, Maverick Ventures — 9 tracked in total.
- Spear Bio has filed 4 Form Ds with the SEC since 2021, most recently Aug 2024 ($45.0M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Spear Bio
Funding rounds
4 roundsAbout Spear Bio
Developer of ultrasensitive protein detection technology designed to offer significant benefits across the healthcare value chain. The company's technology helps in self-testing and telemedicine-based diagnostics that rely on the ability to quantify minuscule amounts of protein biomarkers from at-home collected samples, enabling clinicians with ultrasensitive detection from small sample volumes that fit into existing workflows for sample collection, processing, and detection.
- Sector
- Healthcare
- HQ
- Woburn, MA, United States
- Founded
- 2021
- Employees
- 48
- Website
- spear.bio/
- Ownership
- Privately Held (backing)
Spear Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spear Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spear Bio in its N-PORT filings yet. We sweep new filings monthly.